Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Raises Total of $20M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.

In a document filed with the US Securities and Exchange Commission this week, the Gaithersburg, Md.-based firm disclosed it had raised $11.9 million. According to a company spokesman, the funds raised include part of a $17 million Series B round announced in September and an additional $3 million, making the total raised in the B round $20 million.

The $17 million raised in September was led by jVen Capital and included participation from existing investors CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical, and Versant Ventures. The additional $3 million came from new investors, whom OpGen declined to identify.

The funds will be used for the continued commercialization of OpGen's Argus Optical Mapping System, which uses optical mapping technology for whole-genome sequence assembly and finishing. The system was launched in the spring.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.